Follicular Lymphoma
Conditions
Keywords
Follicular Lymphoma, Mosunetuzomab, Resistance, CD20-CD3, Bispecific antibodies, Neoplasms, Lymphatic Diseases, Immunoproliferative Disorders
Brief summary
Mosunetuzumab is a T-cell bispecific antibody targeting CD20 and CD3 aiming to redirect T cells to engage and eliminate malignant B cells. Bispecific antibodies (BsAb) are a promising treatment option which can induce long-term responses in refractory and relapsed B cell lymphoma patients. However, the factors determining the quality and duration of responses are poorly understood.
Detailed description
the objective is to produce a collection of great scientific interest for lymphoma research from CELESTIMO's clinical trial patients' samples to increase knowledge of treatment with mosunetuzumab's for patients with follicular lymphoma (FL). study population involves patients participating to CELESTIMO study in France. 10 sites are expected in this biobanking protocol study Biological samples will collected as part of routine care (tissue and blood already sampled in routine and/or CELESTIMO study) at screening, at C4, at C12 or at progressive disease/relapse.
Interventions
None listed
Sponsors
Roche Pharma AG
The Lymphoma Academic Research Organisation
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
patients who participate to CELESTIMO study (NCT04712097)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Capacity of sampling | 2 years | number of samples collected |
Countries
France
Outcome results
None listed